Chronic hepatitis B

@article{Lok2002ChronicHB,
  title={Chronic hepatitis B},
  author={Anna S. Lok and Brian J. McMahon},
  journal={Hepatology},
  year={2002},
  volume={45}
}
PREAMBLE These guidelines have been written to assist physicians and other health care providers in the recognition, diagnosis, and management of patients chronically infected with the hepatitis B virus (HBV). They are intended to suggest preferable approaches to the clinical management of chronic hepatitis B. The recommendations are flexible and are not intended as the only acceptable approach to management and treatment. As the appropriate course of treatment will vary in light of the… 
Chronic hepatitis B: Update of recommendations
TLDR
These guidelines were developed under the auspices of, and approved by, the Practice Guidelines Committee of the American Association for the Study of Liver Diseases and were updated in September of 2003.
Management of chronic hepatitis B: consensus guidelines.
The present document presents the proceedings of the consensus development conference on the management of viral hepatitis held in January 2007 under the auspices of the Canadian Association for the
Management of Hepatitis B Virus Infection
TLDR
The goal of this article is to provide nurses with the most current consensus guidelines for the management of CHBV infection and their application in nursing practice to optimize treatment to enhance patient outcomes.
Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines.
TLDR
These guidelines share a common principle regarding NUC treatment for CH-B: long-term viral suppression by the drugs with potent antiviral activity and low rate of development of drug resistance to prevent disease progression.
Current treatment for chronic hepatitis B in Japan
To standardize diagnosis, treatment, and management of chronic hepatitis B, updated treatment guidelines in Japan have been formulated by a research team of the Japanese Ministry of Health, Labor and
A general approach to the management of chronic hepatitis C.
  • L. Dove
  • Medicine
    Gastroenterology clinics of North America
  • 2004
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.
  • E. Keeffe, D. Dieterich, T. Wright
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2006
Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
TLDR
Peginterferon (PEG-IF N) therapy should be considered as initial therapy in both HBeAg-positive and H beAg-negative patients without contraindications for treatment with this drug because of the higher chance of achieving sustained response compared with nucleos(t)ide analogue therapy.
[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
TLDR
The consensus-based guidelines for 2012 stress the importance of quick and detailed virologic evaluations, the applicability of transient elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 436 REFERENCES
The use of lamivudine for patients with acute hepatitis B (a series of cases)
TLDR
In the absence of a randomized, prospective study of lamivudine in patients with severe acute hepatitis B, the data encourage the use of this safe and well tolerated drug.
Management of hepatitis B: 2000--summary of a workshop.
TLDR
This review provides a summary of a 3-day research workshop on September 8 ‐10, 2000 entitled “Management of Hepatitis B: 2000” and concluding recommendations on management of chronic hepatitis B.
Understudied populations with hepatitis C
TLDR
New efforts and new approaches are needed to expand the eligibility for antiviral therapy of hepatitis C and make treatment more available for understudied populations with this disease.
Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children.
TLDR
A consensus was obtained on the use of IFN in children with hepatitis B, based on its short-term efficacy, and the long-term clinical and virological effects of the drug remain to be evaluated.
Hepatitis B: evolving epidemiology and implications for control.
TLDR
A comprehensive approach to eliminating HBV transmission must address infections acquired during early childhood as well as those acquired by teenagers and adults.
Lamivudine for chronic delta hepatitis
TLDR
Lamivudine is a potent inhibitor of HBV‐DNA replication, but does not improve disease activity or lower HDV‐RNA levels in patients with chronic delta hepatitis.
A preliminary trial of lamivudine for chronic hepatitis B infection.
TLDR
In a preliminary trial, 12 weeks of lamivudine therapy was well tolerated, and daily doses of 100 mg and 300 mg reduced HBV DNA to undetectable levels.
Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis
TLDR
Patients with Crohn’s disease who are candidates for infliximab therapy should be tested for hepatitis B serological markers before treatment and considered for prophylaxis of reactivation using antiviral therapy if positive.
...
1
2
3
4
5
...